AIRCHILL Standards, Regulatory Requirements, Cost & Time Matrix

Development planning matrix · Version 1.0 · 29 August 2026

Standards, requirements, cost and time by AIRCHILL subsystem.

A three-market planning matrix for Germany/EU, the United States and China. It separates legal/regulatory requirements from consensus standards and from management estimates. Cost ranges are planning envelopes for external engineering, testing, regulatory and certification work; they are not supplier quotations. Calendar time assumes a reasonably mature design and can overlap across workstreams.

Planning rules

Do not confuse a standard with a legal requirement.

REGULATION

Mandatory legal framework

Examples: EU MDR, FDA QMSR and submission requirements, NMPA registration rules, radio regulations, medical-gas law and clinical-investigation requirements.

STANDARD

Consensus route to evidence

IEC/ISO/EN/ANSI/GB/YY standards usually define accepted ways to demonstrate safety and performance. Applicability, edition and recognition/harmonisation must be frozen for each submission.

COST

Management envelope

Ranges below include external laboratory, consultant, certification and engineering cash cost. They exclude normal internal payroll unless noted. OEM reuse can radically reduce both.

TIME

Calendar, not additive duration

EMC, software, usability and verification can run in parallel. Adding every row would overstate total programme duration.

Architecture rule. For EKG, defibrillator, suction, 5G modem and much of patient monitoring, AIRCHILL should preferentially integrate qualified OEM subsystems. The proprietary development burden should remain concentrated on respiratory cooling, ventilation, gas management and the safety controller. Integration still requires system-level verification.

Horizontal requirements

Requirements that cut across almost every component.

Requirement	Primary standards / rules	EU / Germany	USA	China	Planning time	External planning cost	Status / replacement
Quality management	ISO 13485; design controls; supplier controls	MDR QMS + NB audit as applicable	21 CFR Part 820 QMSR incorporates ISO 13485:2016 since 2 Feb 2026	NMPA device GMP/QMS + local registration quality evidence	4–9 mo initial build; ongoing	€40k–€120k implementation + €15k–€40k initial certification/audit planning	PLANNED Replace with NB/registrar quotation.
Risk management	ISO 14971	MDR Annex I integration	Risk file expected across design/submission	NMPA registration dossier/risk analysis	3–6 mo to mature first file; ongoing	€20k–€70k external support	PLANNED
Electrical safety	IEC/EN 60601-1; China GB 9706.1 family	System + applicable collateral/particular standards	FDA-recognized editions as applicable	GB 9706.1 and applicable GB/YY particulars	3–6 mo test campaign after design freeze	€35k–€100k system-level; more with retests	OPEN Freeze lab + configuration.
EMC	IEC 60601-1-2; radio coexistence where relevant	CE evidence + RED interactions	FDA + FCC/radio evidence where relevant	GB/YY + SRRC/MIIT interactions	2–5 mo	€25k–€80k	OPEN
Alarms	IEC 60601-1-8	Required where applicable to ME system	Same consensus basis	GB/YY implementation	2–4 mo design verification	€15k–€50k incremental	PLANNED
Usability / human factors	IEC 62366-1; FDA HF guidance	MDR usability engineering	Formative + summative validation where critical tasks exist	NMPA human-factors expectations / local user validation as applicable	6–12 mo across formative + summative	€80k–€250k	PLANNED
Software lifecycle	IEC 62304 + architecture, V&V, SOUP control	MDR software evidence	FDA device software documentation	NMPA software registration review	6–18 mo, parallel with product development	€100k–€500k external/V&V depending on software scope	PLANNED
Cybersecurity	IEC 81001-5-1; threat model; SBOM; secure update	MDR + MDCG cybersecurity	FDA premarket cybersecurity + §524B where Cyber Device	NMPA cybersecurity dossier and local data/security requirements	4–9 mo initial evidence; lifecycle ongoing	€70k–€250k incl. penetration testing	PLANNED
Clinical investigation	ISO 14155:2026	MDR Annex XV + ethics/competent authority	IDE/IRB as applicable	NMPA clinical evaluation/trial path	6–18 mo setup before first patient depending on study	€150k–€600k setup before per-patient trial costs	OPEN Replace with CRO/site quotes.
Labelling / UDI	ISO 20417; ISO 15223-1; UDI rules	EUDAMED/UDI obligations	FDA UDI/GUDID as applicable	NMPA UDI database	2–4 mo	€15k–€60k	PLANNED

Subsystem matrix

Component-specific evidence, cost and time.

Subsystem	Core standards / requirements	OEM integration path	Own-development path	EU / Germany focus	USA focus	China focus	Recommended strategy
Respiratory cooling + ventilator	IEC 60601-1/-1-2/-1-8; ISO 80601-2-12 and/or ISO 80601-2-84; ISO 5367/5356; humidification/gas monitoring standards as applicable	6–12 mo; €150k–€450k if using qualified ventilator core but proprietary cooling path	18–36 mo; €1.0m–€3.0m+ before clinical programme	MDR classification + NB; EMS environment if intended	Predicate/product-code strategy; 510(k) vs De Novo must be confirmed	Likely high-class registration; GB/YY test plan + NMPA classification	PROPRIETARY CORE. Keep cooling/gas path and safety controller in-house; reuse mature ventilator technology where feasible.
Electrical suction pump	ISO 10079-1 + IEC 60601 family	2–4 mo; €20k–€60k	6–12 mo; €100k–€300k	System integration + infection/secretions risk	Accessory/finished-device implications under QMSR	GB/YY applicability and local registration if marketed separately	BUY/OEM. Integrate a proven pump; validate condensation/secretions interfaces.
ECG / patient monitor	IEC 60601-2-25 diagnostic ECG; -2-27 monitoring; -2-47 ambulatory; IEC 80601-2-49 multifunction monitor	3–6 mo; €40k–€120k	9–18 mo; €250k–€700k+	Defib protection, alarms, monitoring claims	FDA recognized standards + algorithm claims	GB/YY equivalents and local performance testing	BUY/OEM. Avoid building ECG front-end unless strategically necessary.
Defibrillator / AED	IEC 60601-2-4 + 60601 family; waveform/energy/AED algorithm validation	4–9 mo; €80k–€250k system integration	18–30 mo; €0.8m–€2.5m+	Safety isolation + synchronized cardioversion/AED claims	High scrutiny of shock-advisory algorithm and energy delivery	Local electrical/performance testing + NMPA pathway	BUY/OEM. Integrating a certified defib module is far more efficient than developing one.
SpO₂ / capnography / gas monitoring	ISO 80601-2-61; ISO 80601-2-55 and related monitoring standards	3–6 mo; €40k–€140k	9–18 mo; €250k–€800k	Accuracy across cold/humid gas conditions	Algorithm/sensor claims and labeling	Local type testing and algorithm evidence	BUY/OEM sensors, but validate under AIRCHILL temperature/humidity/He mixtures.
Oxygen / medical-gas delivery	ISO 7396-1; ISO 9170-1; ISO 10524; ISO 5359; ISO 15001; medicinal-gas law	External medical O₂ source: 3–6 mo; €30k–€100k integration	Integrated cylinders/LOX/gas generation: 9–18 mo; €200k–€700k+	Separate medicinal-gas/device boundary	FDA medical gas + device combination analysis	NMPA + Chinese medicinal-gas / combination-product analysis	Use separately supplied medical O₂ first. Delay integral LOX/generation until commercial need justifies complexity.
Helium carrier gas	Gas compatibility, metrology, ventilation standards; medicinal-gas/combination-product assessment	Bench/preclinical physical carrier-gas programme: 6–12 mo; €150k–€500k	Human therapeutic gas claim: 18–36 mo; €0.8m–€3m+ incl. clinical/regulatory work	Clarify whether physical device mode vs medicinal-gas claim	FDA designated medical gas / combination-product interaction	NMPA drug-device combination classification gate	Split claims. First prove physical heat-transfer benefit; only then decide whether to pursue pharmacological/neuroprotective claim.
5G modem / connectivity	RED 2014/53/EU; ETSI EN 301 908 / 301 489; FCC in US; SRRC/MIIT in China; IEC 60601-1-2 coexistence	Certified modem: 3–6 mo; €40k–€120k integration/testing	Own radio hardware: 12–24 mo; €300k–€1m+	RED + MDR interaction	FCC equipment authorization + carrier certification as applicable	SRRC/MIIT + carrier/network requirements	BUY certified module. Never build cellular RF from scratch for first product.
Telemedicine / cloud	IEC 62304; IEC 81001-5-1; IEC 80001; ISO/IEC 27001; ISO 27799; HL7 FHIR; IEEE 11073 where useful	6–12 mo; €150k–€500k for secure supervisory platform	12–24 mo; €500k–€1.5m+ for proprietary safety-critical remote-control architecture	GDPR + MDR software/cybersecurity; local safety must remain independent	HIPAA where applicable + FDA software/cyber evidence	PIPL/data-localization and NMPA cybersecurity implications	Supervisory, not safety-critical control. Device must remain safe offline.
AI assistance	ISO 14971/62304/81001; EU AI Act where applicable; FDA AI/PCCP path; NMPA AI review	Decision-support AI: 6–12 mo; €150k–€500k	Closed-loop therapeutic AI: 18–36 mo; €0.8m–€3m+	MDR + AI Act high-risk analysis where safety component	AI-enabled device software + possible PCCP	NMPA algorithm/data validation and local evidence	Start advisory. Keep first closed-loop control deterministic; add AI later after stable device data exist.
Battery / power / EMS environment	IEC 60601-1; IEC 60601-1-12 for EMS; applicable battery transport/safety standards	4–8 mo; €60k–€180k	9–18 mo; €200k–€600k for custom pack/BMS architecture	Transport shock/vibration, ingress, runtime, charger safety	Same plus transport/shipping requirements	GB/YY + local battery/radio logistics	Use qualified battery modules where possible, but validate integrated runtime under maximum cooling/gas load.

Market overlays

Incremental time and cash by jurisdiction.

Market	Regulatory planning case	Incremental calendar after common technical file is mature	Incremental external cash planning	Known official fee examples	Main uncertainty
EU / Germany	Current conservative planning hypothesis: MDR Class IIb for minimum certifiable configuration; confirm with Notified Body / competent authority.	9–18 mo from mature design dossier to certification planning case	€150k–€500k NB/regulatory/certification layer, excluding major new clinical trial	No single statutory CE fee; NB fees are commercial quotations.	Final intended purpose, classification, gas architecture, clinical evidence expectations.
USA	Pre-Sub first; 510(k) if acceptable predicate/claim path exists, De Novo fallback if not.	+4–9 mo for 510(k)-type path; +9–18 mo for De Novo planning case, excluding new clinical data generation	€100k–€400k submission/testing gap for 510(k)-type path; €250k–€800k+ for De Novo preparation before clinical expansion	FY2026 FDA fees: 510(k) $26,067 standard / $6,517 small business; De Novo $173,782 / $43,446; establishment registration $11,423.	Predicate, product code, significant-risk/IDE status, gas/combination-product determination.
China	Classification/attribute determination first; imported high-risk planning case where applicable.	+6–18 mo over common dossier; potentially longer if local type testing or clinical work is required	€150k–€600k+ localization, agent, testing, translation and registration planning; clinical study additional	Do not insert a fabricated national single fee; obtain current NMPA/local testing/agent quotations.	Exact class, mandatory GB/YY standards, local type testing, clinical evaluation exemption/requirements, combination-product status.

Do not add the market durations linearly. A strong global architecture should produce one core design-history/risk/software/verification package, then add jurisdiction-specific deltas. The largest savings come from freezing one hardware configuration and one evidence hierarchy before country submissions diverge.

Programme-level view

What the first certifiable platform could cost and how long it could take.

LEAN OEM-INTEGRATION

~18–30 months · €2.5m–€5m

Uses qualified OEM EKG/monitoring, defibrillator, suction, 5G, batteries and mature ventilator elements. AIRCHILL develops cooling/gas path, safety controller, software integration, system V&V and regulatory evidence.

BASE GLOBAL PLATFORM

~24–36 months · €4m–€8m

Broader EU-first platform with substantial custom respiratory/gas engineering, complete system verification, human factors, cybersecurity and parallel FDA/NMPA preparation. Excludes a large pivotal efficacy RCT.

HIGH CUSTOMIZATION

~36–60 months · €8m–€15m+

Own defibrillator/monitoring/radio or safety-critical AI, integrated gas-generation/LOX, major novel clinical claims or multiple divergent country configurations. This path should be avoided unless commercially necessary.

Key cost lever. The fastest way to reduce both certification risk and cash burn is not to remove useful functions from AIRCHILL, but to buy mature functions as qualified OEM modules and spend proprietary engineering where AIRCHILL is differentiated: respiratory cooling, gas handling, thermal control, measurement, safety logic and clinical evidence.

All programme totals are MANAGEMENT ENVELOPES, not quotations and not financing commitments. They should be replaced progressively with named laboratory, notified-body, CRO, OEM and regulatory-consultant quotes. Clinical efficacy trials are budgeted separately in the Clinical Study Planner.

Source and update layer

What is sourced and what is still an assumption.

FDA 2026

QMSR

FDA QMSR became effective 2 February 2026 and incorporates ISO 13485:2016 into 21 CFR Part 820. FDA source.

FDA FEES

FY2026 MDUFA

Current official FDA user-fee values are copied from the FY2026 MDUFA schedule and should be updated annually. FDA fee schedule.

MANAGEMENT ESTIMATE

Testing / certification / engineering ranges

These ranges are not regulatory facts. They represent an internal planning envelope and should be superseded by supplier and laboratory quotations.

VERSION CONTROL

Freeze applicable editions later

The exact harmonized/recognized GB, YY, EN, IEC and ISO editions must be frozen against the final architecture and submission date. Standards can change while the product is in development.

Regulatory & Reimbursement · Clinical Study Planner · Translational & Human Performance Pipeline · Sources, Assumptions & Data Gaps